INVERSAGO-PHARMA
24.1.2023 13:01:37 CET | Business Wire | Press release
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2, 2023.
For additional information or to request a meeting with management, please contact conference representatives.
About Inversago Pharma
Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005328/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABZ Innovation Opens One of Europe's Largest Civilian Drone Manufacturing Facilities17.9.2026 11:43:00 CEST | Press release
New facility in Szentendre, Hungary strengthens Europe's manufacturing capacity for agricultural and industrial drone technology ABZ Innovation, a European developer and manufacturer of heavy-duty civilian drones for agricultural and industrial use, today officially opened its new manufacturing facility in Szentendre, Hungary — one of the largest dedicated civilian drone production sites in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917072041/en/ ABZ Innovation's new manufacturing facility in Hungary — one of the largest dedicated civilian drone production sites in Europe. The new facility is approximately four times larger than ABZ Innovation's previous production site, supporting a targeted threefold increase in production during 2026 alone, with a further doubling planned for 2027. This significantly expands ABZ Innovation's capacity to meet accelerating global demand for drone-based automation in agricultu
INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 11:00:00 CEST | Press release
INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into
LTM Honoured with Avasant Digital Masters Award 202617.9.2026 11:00:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that it has been recognized with the Digital Masters Award 2026 in the Innovator category by Avasant, a leading management consulting firm. The award recognizes LTM's commitment to innovation, excellence, and its ability to drive transformative business outcomes for clients through its portfolio of AI-powered offerings. The award was presented during the Digital Masters Awards Ceremony at Partner Connect 2026 in Los Angeles. LTM was among the 18 service providers shortlisted from a field of over 76 global technology service providers assessed by Avasant for this year's Digital Masters Awards. This recognition reflects LTM's strong leadership, domain expertise, and continued contribution to delivering exceptional value for clients globally. "This recognition reflects our focus on helping clients leverage AI to accelerate transformation, create measurable business value, and stay ahead in a rapidly e
IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 09:43:00 CEST | Press release
Eldorado will house an IQM Spark at their Campinas headquarters and will also access IQM's 54-qubit cloud-based system, pairing on-premises hardware with larger-scale capability via the cloud. This will enable innovation and growth to scale with their quantum knowledge development. This is the first quantum computer purchase by a private research institute in Brazil, which will enable researchers, engineers, universities, and industry partners to advance research and build capability locally. IQM and Eldorado aim to accelerate quantum adoption across Brazil and South America by building expertise locally and opening the system to Eldorado's network of universities, startups and industry partners. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimed
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 08:00:00 CEST | Press release
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. Approval includes both children and adolescents who are able to walk and those who are non-ambulant, broadening the population eligible for XEOMIN treatment Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in childr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom